It is known that reversible thyroid dysfunction occurs in up to 60% of metastatic cancer patients treated with immunotherapy consisting of IL-2 alone or in combination with interferon-α or lymphocyte-activated killer cells. This evidence concerns the gene IL2 and metastatic malignant neoplasm.